Corona Remedies Limited ranks among the top 30 pharmaceutical companies in the Indian Pharmaceutical Market (IPM

$CORONA Corona Remedies Limited ranks among the top 30 pharmaceutical companies in the Indian Pharmaceutical Market (IPM). It focuses heavily on chronic care and therapeutic segments, capturing strong market positions:Women's Healthcare: Ranked #5 in India, reaching roughly 85% of gynecologists and IVF specialists ***** Management: Ranked #5 in India, offering formulations for acute and chronic pain ***** Ranked #20, addressing metabolic and cardiovascular ***** Ranked #9, focusing on specialist-driven urological medications.📊 Stock & Financial HighlightsCorona Remedies is a publicly traded entity on the Indian stock ***** Capitalization: Approximately ₹13,063 ***** Price: Trading at around ₹2,***** Metrics: It has delivered a strong profit growth of 23.3% CAGR over the past 5 years with a 3-year Return on Equity (ROE) of 26.5%.Dividend Yield: The company maintains a healthy dividend payout ratio of 29.4%.💡 Recent DevelopmentsThe company recently commercialised its state-of-the-art, EU-approved Women's Hormone Manufacturing Facility in Bhayla, Ahmedabad. This 1.0 lakh sq. ft. facility expands their capacity to 194 million tablets/capsules annually, driving high-margin growth in the specialized hormone therapy market.